Status | Study |
Not yet recruiting |
Study Name: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Condition: Adrenal Cortex Carcinoma Adult Alveolar Soft Part Sarcoma Date: 2016-08-15 Interventions: Drug: Cabozantinib S-malate Gi |
Recruiting |
Study Name: Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Condition: Advanced Adult Hepatocellular Carcinoma Localized Non-Resectable Adult Hepatocellular Carcin Date: 2014-02-24 Interventions: Other: Laboratory Biomarker Analysis |
Active, not recruiting |
Study Name: Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Condition: Adult Cholangiocarcinoma Advanced Adult Hepatocellular Carcinoma Date: 2014-01-20 Interventions: Drug: Capecitabine Given PO |
Completed |
Study Name: Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Condition: Childhood Hepatocellular Carcinoma Papillary Thyroid Cancer Date: 2011-12-29 Interventions: Drug: sorafenib tosylate Given |
Withdrawn |
Study Name: Biomarkers in Stored Tumor Samples From Younger Patients With Liver Cancer Condition: Liver Cancer Date: 2009-05-09 Interventions: Genetic: comparative genomic hybridization |
Recruiting |
Study Name: Collecting and Storing Tissue From Young Patients With Cancer Condition: Cancer Date: 2009-05-09 Interventions: Genetic: DNA analysis Genetic: reverse tra |
Withdrawn |
Study Name: Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery Condition: Liver Cancer Date: 2007-05-08 Interventions: Biological: recombinant interferon alfa-2b |
Withdrawn |
Study Name: Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer Condition: Liver Cancer Date: 2006-01-12 Interventions: Drug: cisplatin Drug: cyclophosphamide |
Completed |
Study Name: Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Condition: Cancer Date: 2005-09-08 Interventions: Biological: therapeutic allogeneic lymphocytes The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/k |
Completed |
Study Name: Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Condition: Childhood Central Nervous System Germ Cell Tumor Childhood Extragonadal Germ Cell Tumor Date: 2004-09-07 Interventions: Drug: oxaliplatin Given IV Other Names: |